T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.

Pharmaceutical

T3D Therapeutics

John Didsbury

Jessica Stanek

Hoda Gabriel

Blake Swearingen

Stan Chamberlain

Warren Strittmatter

The board of directors at T3D Therapeutics has a history of experience with advisory boards, consulting, and mentoring. The board members have also attended top universities for their education, including the University of Southern California and the University of Akron School of Law.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at T3D Therapeutics

Leadership Team

CEO and Executive Team